Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Steinfeld, S. D.
Right arrow Articles by Appelboom, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinfeld, S. D.
Right arrow Articles by Appelboom, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 1999; 38: 814-817
© 1999 British Society for Rheumatology

Zidovudine in primary Sjögren's syndrome

S. D. Steinfeld, P. Demols1, J.-P. Van Vooren2, E. Cogan2 and T. Appelboom

1 Divisions of Rheumatology, Ophthalmology and
2 Internal Medicine, Erasmus Academic Hospital, Université Libre de Bruxelles, Brussels B-1070, Belgium

Correspondence to: S. D. Steinfeld, Division of Rheumatology, Erasmus Academic Hospital, Université Libre de Bruxelles, 808 route de Lennick, Brussels B-1070, Belgium.

Objective. To evaluate the efficacy of the administration of zidovudine (AZT), an antiretroviral drug, in patients with primary Sjögren's syndrome (SS).

Methods. Seven female patients (age 57±8.6 yr) with primary SS were enrolled in an open, uncontrolled trial of AZT (250 mg b.i.d.) for the treatment of primary SS. The efficacy variables were oral and ocular dryness symptoms, fatigue, tender points, physician's and patient's global assessments (GA), ocular function tests (fluorescein tear break-up time, Schirmer's test, Rose Bengal staining) and laboratory parameters [erythrocyte sedimentation rate (ESR), serum IgG, IgA and IgM].

Results. A significant improvement was observed in all subjective manifestations, as well as the objective parameters of ocular dryness. The treatment was well tolerated, except for mild and transitory gastrointestinal disturbances in 6/7 patients. Laboratory parameters did not change significantly. The clinical benefit persisted in 5/7 patients 1 month after the end of therapy.

Conclusion. AZT seems to be effective and well tolerated in patients with primary SS.

KEY WORDS: Zidovudine, Sjögren's syndrome, Retrovirus.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
G. D. Panayiotakopoulos, K. Aroni, D. Kyriaki, S. Paikos, N. Vouyioukas, A. Vlachos, A. N. Kontos, and T. Kordossis
Paucity of Sjogren-like syndrome in a cohort of HIV-1-positive patients in the HAART era. Part II
Rheumatology, October 1, 2003; 42(10): 1164 - 1167.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.